Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptive Biotechnologies Corporation filings document financial results, governance matters, registered common stock, and material events for a commercial-stage biotechnology issuer. Recent 8-K reports furnish quarterly and annual operating results, press releases, investor presentation materials, and disclosures tied to the company’s MRD business and immune medicine platform.
The company’s proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and related governance disclosures. Other filings identify ADPT common stock listed on Nasdaq and disclose material agreement activity connected to research and development collaborations, including immune medicine and TCR-antigen programs.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an automatic share sale tied to equity compensation. On the RSU vesting date, 38,074 shares of common stock were sold to cover tax withholding obligations under a mandated “sell to cover” arrangement, rather than as a discretionary trade.
After this tax-related sale, Francis Lo directly owned 321,967 common shares. An additional 2,500 common shares were reported as indirectly owned through Lo’s spouse, You Jin Lee.
Adaptive Biotechnologies Corp director Peter M. Neupert reported an acquisition of common stock through a grant or award. On March 4, 2026, he received 15,625 shares at a stated price of $0.0000 per share, bringing his directly owned holdings to 240,315 shares of common stock.
Adaptive Biotechnologies Corp director Robert Hershberg reported an award of common stock. On March 4, 2026, he acquired 15,625 shares of common stock through a grant with a stated price of $0.00 per share. Following this award, his direct holdings total 62,347 shares of common stock.
Adaptive Biotechnologies Corp reported that its Chief People Officer, Francis Lo, acquired 44,063 shares of common stock on March 4, 2026 through a stock grant at no cost, described as a grant, award, or other acquisition. Following this equity award, Lo directly holds 360,041 common shares. The filing also notes an additional 2,500 common shares held indirectly through Lo’s spouse, You Jin Lee.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky received two awards of common stock on March 4, 2026. She acquired 59,375 shares in one grant and 62,500 shares in another, both at a reported price of $0.00 per share, increasing her directly held stake.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, Immune Medicine, Sharon Benzeno acquired 39,063 shares of common stock on March 4, 2026 through a grant or award at a stated price of $0.00 per share. Following this award, Benzeno directly holds 335,854 common shares.
RUBINSTEIN JULIE reported acquisition or exercise transactions in this Form 4 filing.
Adaptive Biotechnologies Corp reported that President and COO Julie Rubinstein received a grant of 81,250 shares of Common Stock on March 4, 2026. The award was recorded at a price of $0.0000 per share, indicating it was granted for no cash consideration. Following this equity grant, Rubinstein’s directly owned holdings increased to 656,485 shares of Common Stock, reflecting a larger personal stake in the company.
Adaptive Biotechnologies Corp reported that Chief Scientific Officer Harlan S. Robins acquired shares of common stock through stock awards. On March 6, 2026, he received 709,220 shares at a price of $0.00 per share, and on March 4, 2026, he received 127,813 shares at $0.00 per share.
These awards relate to performance share units granted on March 6, 2023 for a three-year period ending March 6, 2026. The company certified achievement of the performance goals on March 6, 2026, and the performance share units vested on that date, resulting in common stock delivery.
Adaptive Biotechnologies Corp reported that its Chief Financial Officer, Kyle Piskel, acquired 61,875 shares of common stock as a grant or award on March 4, 2026. The shares were recorded at a price of $0.00 per share, indicating they were not purchased on the open market but received as compensation. Following this transaction, Piskel directly owned 278,512 shares of Adaptive Biotechnologies common stock.
OWEN KATEY EINTERZ reported acquisition or exercise transactions in this Form 4 filing.
Adaptive Biotechnologies Corp director Katey Einterz Owen received an equity award of 15,625 shares of Common Stock on March 4, 2026. The shares were granted at a price of $0.00 per share, indicating a stock award rather than an open‑market purchase. Following this grant, her directly held Common Stock increased to 88,254 shares, reflecting her updated ownership position as a company director.